SCHEMBL4344682

SCHEMBL4344682

NC(=S)N(Cc1cccnc1)N=Cc1ccc(-c2ccc(Cl)cc2Cl)o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 4/20 0.42
HPGD P15428 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
MAPK1 P28482 2/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
POLB P06746 3/20 0.39
GAA P10253 2/20 0.39
MCL1 Q07820 2/20 0.39
HTT P42858 1/20 0.38
PDK1 Q15118 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336312 0.93 ALDH1A1 (0.51) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4323303 0.90 KDM4E (0.42) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4329107 0.87 ALDH1A1 (0.45) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4334594 0.86 MAPT (0.46) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4333822 0.84 ALDH1A1 (0.50) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4333786 0.84 SLC9A1 (0.38) MAPTALDH1A1KMT2ALMNANPSR1
SCHEMBL4338798 0.82 CYP2A6 (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4340661 0.80 CYP2A6 (0.42) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4341378 0.80 MAPT (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4329307 0.80 MAPT (0.48) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885ALDH1A1 1459/4885KDM4E 3010/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885ALDH1A1 1173/4885KDM4E 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.